Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA
• Company gains further clarity on the additional information required to advance its PMA review • FDA did not request an additional clinical trial following its 100-day review of the PMA application • Company does not currently expect a material change to its overall regulatory timeline TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Spectral Medical […]
Financial Post
First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 60.7 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.2 of 35
- Source authority
- 7 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · US & Canada · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (1), Toronto (9), In-Person FDA (none), PMX PMA (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.